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Abstract
Despite appropriate antifungal treatment, the management of cryptococcal disease remains challenging, especially in immunocompro-
mised patients, such as human immunodeﬁciency virus-infected individuals and solid organ transplant recipients. During the past two
decades, our knowledge of host immune responses against Cryptococcus spp. has been greatly advanced, and the role of immunomodula-
tion in augmenting the response to infection has been investigated. In particular, the role of ‘protective’ Th1 (tumour necrosis factor-a,
interferon (IFN)-c, interleukin (IL)-12, and IL-18) and Th17 (IL-23 and IL-17) and ‘non-protective’ Th2 (IL-4, IL-10, and IL-13) cytokines
has been extensively studied in vitro and in animal models of cryptococcal infection. Immunomodulation with monoclonal antibodies
against the capsular polysaccharide glucuronoxylomannan, glucosylceramides, melanin and b-glucan and, lately, with radioimmunotherapy
has also yielded promising results in animal models. As a balance between sufﬁciently protective Th1 responses and excessive inﬂamma-
tion is important for optimal outcome, the effect of immunotherapy may range from beneﬁcial to deleterious, depending on factors
related to the host, the infecting organism, and the immunomodulatory regimen. Clinical evidence supporting immunomodulation in
patients with cryptococcal infection remains too limited to allow ﬁrm recommendations. Limited human data suggest a role for IFN-c.
Identiﬁcation of surrogate markers characterizing patients’ immunological status could possibly suggest candidate patients for immuno-
therapy and the type of immunomodulation to be administered.
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Introduction
The genus Cryptococcus includes 37 recognized basidiomyce-
tous yeast species [1]. Human disease is mainly caused by
Cryptococcus neoformans and Cryptococcus gattii [1]; other spe-
cies, such as Cryptococcus laurentii and Cryptococcus albidus,
have rarely been reported to affect humans [2]. C. neofor-
mans has a global geographical distribution; C. gattii infections
have been reported from tropical and subtropical regions
and from the outbreak that emerged in the temperate area
of British Columbia in 1999 and then expanded towards
Washington, Oregon, and California [1–4]. C. neoformans
affects mainly immunocompromised individuals, such as those
with advanced human immunodeﬁciency virus (HIV) infec-
tion, solid organ transplant recipients, and patients receiving
immunosuppressive agents, including high-dose steroids and
monoclonal antibodies (mAbs) [1]. Indeed, cryptococcal
meningitis is the leading cause of death in HIV-infected indi-
viduals worldwide, with a global burden of approximately
1 million cases occurring each year [5]. It appears that most
infections in HIV patients are caused by C. neoformans var.
grubii (serotype A), and fewer are caused by C. neoformans
var. neoformans (serotype D) [6,7]. C. gattii, in contrast, has
been associated with infections in immunocompetent individ-
uals [3].
The management of cryptococcal disease remains challeng-
ing, especially in immunocompromised patients. The combi-
nation of highly active antiretroviral therapy with antifungal
treatment in HIV-infected individuals has reduced the 12-
month and 24-month mortality rates to 25% and 34%,
respectively, as compared with corresponding rates of 54%
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and 76% in the period before highly active antiretroviral
therapy. However, the 3-month mortality rate of acute cryp-
tococcal meningoencephalitis in HIV-infected patients still
approximates 20% [8]. Similarly, the 3-month mortality rate
of solid organ transplant recipients with cryptococcosis in a
recent retrospective study was 28.6% [9]. These data high-
light the need for optimization of treatment of Cryptococcus
infections by means of newer approaches and potential
adjunctive therapies. In this context, the potential for resto-
ration and optimal enhancement of host defence mechanisms
through immunomodulation has attracted wide scientiﬁc
interest. The present review will concisely present human
immune responses against Cryptococcus and then discuss
recent developments in the immunotherapy of cryptococcal
infections.
Overview of Immune Responses Against
Cryptococcus
Cryptococcus enters the human body by inhalation. Following
adherence to and internalization of the organisms by pulmo-
nary epithelial cells, pulmonary alveolar macrophages, and
dendritic cells, infection is usually contained, and leads to
mild or no symptoms in the majority of immunocompetent
individuals. If the yeast evades the host immune mechanisms,
as is the case in immunocompromised patients, it dissemi-
nates to other organs, particularly the brain [1]. Cryptococcus
possesses a number of mechanisms by which it overcomes
host responses; these include the formation of a polysaccha-
ride capsule, the production of melanin and virulence-related
enzymes (such as phospholipase B1 and urease), and its abil-
ity to grow at 37C and live as an intracellular pathogen in
host cells [10,11].
The innate immune response against Cryptococcus encom-
passes both the complement system and phagocytic effector
cells (dendritic cells, macrophages, and neutrophils). The role
of the complement system is to stimulate chemotaxis of
phagocytic cells and opsonize the pathogen in order to facili-
tate phagocytosis [11]. In vitro data suggest a key role for the
alternative complement pathway in cryptococcosis [12,13];
however, optimal opsonization requires the contribution of
the classical pathway as well [14]. Both complement activa-
tion and phagocytosis appear to be inhibited by the crypto-
coccal polysaccharide capsule [10].
Phagocytosis of cryptococcal cells follows direct recogni-
tion of conserved yeast structures (such as the capsular
polysaccharide glucuronoxylomannan and mannoproteins)
[15,16] or opsonization of yeast cells via complement or
antibodies [17]. Dendritic cells are able to phagocytose
C. neoformans, and subsequently act as major antigen-pre-
senting cells and modulators of adaptive immune responses
[18,19]. It appears that dendritic cells are more potent in-
ducers of T-cell responses than macrophages [18,20]. The
latter play a complicated but not always beneﬁcial role in the
host response during cryptococcal infection. Indeed, follow-
ing phagocytosis by the macrophages, C. neoformans is able
to survive and replicate in the phagolysosomes, thus escaping
other protective host immune responses and maintaining a
state of latent infection [21–24]. Subsequently, Cryptococcus
can exit macrophages and remain in the extracellular envi-
ronment (causing, for example, fungaemia) or be transferred
from one macrophage to another, maintaining the latent
phase [25,26]. Neutrophils exert their antifungal activity both
by direct oxidative killing of cryptococcal cells and by pro-
duction of antimicrobial peptides, such as the defensins [27–
31].
The adaptive immune response against Cryptococcus
includes antibody-mediated and cell-mediated responses.
During cryptococcal infection, both protective and non-pro-
tective anticryptococcal antibodies may be formed [32–34].
Protective antibodies activate the classical complement path-
way or opsonize yeast cells through complement-indepen-
dent mechanisms [35,36]. Part of their protective activity
also appears to be exerted through interaction with ele-
ments of cell-mediated immunity [11]. Cell-mediated immune
responses against Cryptococcus include both direct cytotoxic
effects and regulation of cytokine production. Direct cyto-
toxic effects are exerted by natural killer (NK), CD4+ and
CD8+ cells, and are mediated by secreted proteins (perforin
and granulysin) [11,37–40]. Cytokine production involves
protective Th1 (tumour necrosis factor (TNF)-a, interferon
(IFN)-c, interleukin (IL)-12, and IL-18) and Th17 (IL-23 and
IL-17) responses and non-protective Th2 (IL-4 and IL-13)
responses. A Th1–Th17 cytokine proﬁle is associated with
increased phagocytic activity and inhibition of Cryptococcus
proliferation [41–44], whereas a Th2 proﬁle is associated
with decreased ability of the host to effectively control the
infection [45,46]. However, an exaggerated Th1 response
may lead to extensive inﬂammation and suboptimal outcome
for the host; sustainment of an optimal Th1–Th2 balance is
now known to be mediated by cd T-cells [47].
Immunotherapy of Cryptococcal Infections:
Preclinical Studies
In vitro and in vivo studies on the immunomodulation of cryp-
tococcal infections have mainly focused on two ﬁelds: the
role of cytokines, and the role of mAbs (Table 1).
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Preclinical studies involving cytokines
A number of studies have demonstrated the protective effect
of Th1 cytokines during experimental cryptococcal infection.
In a murine model of C. neoformans pulmonary and dis-
seminated infection, early administration of IL-12 resulted in
marked inﬁltration of inﬂammatory cells and a reduction in
the number of viable yeast cells in the lung, suppressed dis-
semination to the brain, and increased survival rate of
infected mice. IL-12 treatment was associated with induction
of IFN-c production in the lungs of infected mice. Late
(7 days after inoculation) administration of IL-12 was not
associated with a protective effect in this model [48]. In
another murine model of systemic cryptococcosis, adminis-
tration of IL-12 signiﬁcantly reduced the level of brain and
liver infection (quantiﬁed as CFUs of C. neoformans); in the
same study, IL-12 enhanced the antifungal effect of ﬂuconaz-
ole [49]. In a murine model of chronic C. neoformans infec-
tion, long-term administration of exogenous IL-12 reduced
the fungal burden in various organs and prevented the death
of infected mice [50].
The protective effect of another Th1 cytokine, IL-18, has
also been demonstrated in a murine model of pulmonary
and disseminated cryptococcosis. Treatment with recombi-
nant murine IL-18 in this study enhanced elimination of Cryp-
tococcus from the lungs, inhibited dissemination to the
central nervous system, and prolonged the survival of
infected mice. IL-18 treatment was associated with increased
levels of serum IFN-c; administration of neutralizing anti-IFN-
c antibodies abrogated the protective effect of IL-18 [51]. A
synergistic interaction of IL-18 with IL-12 has been shown in
the induction of anticryptococcal activity of NK cells [52].
This synergistic interaction was subsequently demonstrated
in a murine model of pulmonary and disseminated cryptococ-
cosis, where combined IL-18 and IL-12 treatment prolonged
the survival of infected mice and reduced fungal load in the
lung and brain; this effect was mediated by enhancement of
IFN-c production by NK and cd T-cells and suppression of
IL-4 production in the lungs [53].
The contribution of IFN-c in controlling cryptococcal
infection has been shown in murine models of lung and dis-
seminated cryptococcosis, where IFN-c administration pro-
longed survival and reduced fungal burden in the lungs and
brain [54–58]. In some of these studies, IFN-c also enhanced
the efﬁcacy of amphotericin B treatment of mice in terms of
survival prolongation and reduction of CFUs in various
organs (brain, liver, kidneys, and lungs) [54,56,57]. The pro-
tective effect of IFN-c in mice against Cryptococcus appears,
however, to contradict the results of in vitro studies involving
human cells. Addition of IFN-c resulted in loss of growth
inhibition of C. neoformans by human peripheral blood cul-
tured monocyte-derived macrophages [59]. Similarly, IFN-c
decreased the fungistatic capacity of human alveolar macro-
phages against C. neoformans in vitro [60]. These studies sug-
gest that the regulation of the anticryptococcal functions of
macrophages by cytokines may differ between humans and
mice.
The role of other cytokines in enhancing immune
responses against Cryptococcus has been demonstrated in a
number of in vitro and in vivo studies. Addition of TNF-a
increased the nitric oxide-mediated anticryptococcal activity
of murine macrophages in vitro [61]. The combination of
TNF-a with granulocyte–macrophage colony-stimulating fac-
tor acted synergistically in enhancing the complement-depen-
dent phagocytosis of C. neoformans by murine macrophages
[62]. In a murine model of disseminated cryptococcosis, the
combination of an agonist antibody against CD40 (anti-
CD40), a member of the TNF-a receptor family, with IL-2
prolonged the survival of infected mice and decreased yeast
burdens in brain and kidney; this beneﬁcial effect was medi-
ated through increased IFN-c production [63]. The same
TABLE 1. Immunotherapy of cryptococcal infections: comparative data of preclinical and clinical studies
Immunomodulatory agent Preclinical studies Clinical studies
Th1 cytokines Protective effect of IL-12 and IL-18 in animal models [48–53]
Protective effect of IFN-c in animal models; synergism with
antifungal drugs [54–58]
Inhibitory effect of IFN-c in fungistatic activity of human
macrophages against Cryptococcus [59,60]
Stimulatory/protective effect of TNF-a and IL-2 [61–64]
Correlation between TNF-a, IFN-c and IL-6 levels and
survival/clearance of infection in HIV-infected patients
with cryptococcal meningitis [93]
Increased levels of TNF-a, IL-6 and IL-8 in the CSF of
patients with meningeal vs. extrameningeal infection
and in HIV-negative vs. HIV-positive patients [95]
Phase 2 study of rIFN-c1b as adjunctive therapy in
HIV-infected patients with cryptococcal meningitis:
trend towards more rapid sterilization of CSF and
improved combined mycological–clinical response
[96]
Monoclonal antibodies (mAbs) Protective effect of mAbs targeting glucuronoxylomannan,
glucosylceramides, melanin or b-glucan in vitro and in animal
models [65–87]
Protective effect of radiolabelled mAbs (188Re-labelled 18B7
and 213Bi-labelled 18B7) in animal models [88–92]
Phase 1 dose escalation study of mAb 18B7 administration
in HIV-infected patients with cryptococcal meningitis:
modest and transient reduction of serum cryptococcal
antigen titres; doses up to 1 mg/kg well tolerated [98]
CSF, cerebrospinal ﬂuid; HIV, human immunodeﬁciency virus; IFN, interferon; IL, interleukin; rIFN, recombinant interferon; TNF, tumour necrosis factor.
128 Clinical Microbiology and Infection, Volume 18 Number 2, February 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 126–133
combination (anti-CD40 and IL-2) also prolonged the survival
of mice infected intracerebrally with C. neoformans; this effect
correlated with activation of microglial cells. IFN-c was again
an important mediator of the anticryptococcal activity of this
combination [64].
Preclinical studies involving mAbs
The immunomodulatory effect of mAbs in the course of
experimental cryptococcal infection has been demonstrated
and extensively studied over the last three decades. Most of
these studies have utilized mAbs against glucuronoxyloman-
nan [65–67]; mAbs targeting glucosylceramides [68,69], mela-
nin [70] and b-glucan [71] have also been studied. The
immunomodulatory effects of mAbs appear to be exerted in
a complex and pleiotropic manner through enhancement of
opsonization and phagocytosis [71,72], direct inhibition of
fungal cell growth [68,70,71], reduction of capsule thickness
[71], and, importantly, modulation of cytokine production
and inﬂammation [73–75].
Passive immunization with mAbs in the case of cryptococ-
cal infection may result in protection, non-protection, or
even disease enhancement, depending on the mAb dose and
other characteristics, as well as host immune parameters
[67,76]. In particular, the outcome may be affected by the
relationship between the amount of mAb administered and
the fungal inoculum; under certain conditions, a prozone-like
effect has been observed, with high mAb doses being less
effective than smaller mAb doses [72,77]. Among other fac-
tors, the antibody subclass [78] and isotype [79,80], epitope
speciﬁcity [34], availability of T-cells [81] and B-cells [75] in
the host, presence of nitric oxide [82] and production of
Th1 and Th2 cytokines [73] have been shown to inﬂuence
the outcome of passive immunization studies.
The protective effect of mAbs in murine models of cryp-
tococcal infection has mostly consisted of prolongation of
survival in treated vs. untreated animals [67,69,70,75,79,82–
85]. Administration of mAbs also has been associated with a
reduction of fungal burden in the lungs [70,86], brain
[70,71,84], liver [71,87] and spleen [86,87] of treated mice.
Prolonged survival in animals treated with mAbs was more
frequently associated with downregulation [69,74,75] than
with enhancement [82] of the inﬂammatory response.
Over the past several years, a novel approach, radioimmu-
notherapy, has been developed as an adjunctive immuno-
modulatory treatment for cryptococcal infections. The
concept of radioimmunotherapy is to use radiolabelled mAbs
in order to deliver cytotoxic radiation to fungal cells; in this
way, an antibody without inherent anticryptococcal activity
can be converted into a fungicidal molecule. Indeed, in a
murine model of systemic cryptococcosis, administration of
b-emitter (188Re)-labelled or a-emitter (213Bi)-labelled mAb
18B7 was associated with prolonged survival and reduced
fungal burden in the lungs and brain of treated animals as
compared with controls, without apparent toxicity [88]. The
protective effect of 188Re-labelled 18B7 and 213Bi-labelled
18B7 in cryptococcal infection appears to be mediated
through promotion of apoptosis-like death of yeast cells, a
decrease in the size of the cryptococcal capsule, a synergistic
interaction with macrophages, and modulation of the inﬂam-
matory response [89]. Radioimmunotherapy was shown to
be relatively safe in mice, and maximum tolerated doses
were determined. With these doses, only transient haemato-
logical toxicity and no evidence of pulmonary ﬁbrosis were
observed [90]. In more recent studies, radioimmunotherapy
with 188Re-labelled 18B7 (which has a much longer half-life
than 213Bi-labelled 18B7) increased survival in mice infected
with a high inoculum of C. neoformans and did not select for
yeast cells resistant to radiation [91]. Furthermore, radioim-
munotherapy with 213Bi-labelled 18B7 was more effective
than amphotericin B in decreasing fungal burden in the lungs
and brain of mice infected with C. neoformans [92].
Immunotherapy of Cryptococcal Infections:
Clinical Studies
In contrast to the abundance of in vitro and in vivo studies on
the immunomodulation of cryptococcal infections, relevant
clinical data are very limited (Table 1).
In a series of 62 patients receiving antifungal therapy for
HIV-associated cryptococcal meningitis, the concentrations
of TNF-a, IFN-c, IL-6 and IL-8 in the cerebrospinal ﬂuid
(CSF) were signiﬁcantly higher in survivors than in non-sur-
vivors. Negative correlations were found between log TNF-
a, IFN-c and IL-6 levels and the baseline CFU level of Cryp-
tococcus in the CSF. Log TNF-a, IFN-c, IL-6 and granulocyte
colony-stimulating factor concentrations in the CSF corre-
lated positively with the rate of fall of log CFU. In multivari-
ate analysis, the two factors independently associated with
the rate of clearance of infection were treatment group and
log IFN-c level [93]. The same group of investigators
reported very low concentrations of IFN-c, TNF-a and IL-6
in the CSF of an apparently immunocompetent, HIV-sero-
negative patient with C. gattii meningitis [94], as compared
with the levels found in patients with HIV-related C. neofor-
mans meningitis of the previous study [93]. In the same
patient, the CSF concentration of IL-10 was very high; taken
together, these data suggest a distorted immune response
to C. gattii exposure, allowing progression to meningitis
[94].
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In another study, the levels of TNF-a, IL-6, IL-8, IL-10 and
soluble TNF receptor II were measured in the CSF of 51
HIV-positive and seven HIV-negative patients with culture-
conﬁrmed cryptococcosis. With the exception of IL-10, the
concentrations of the above mediators were higher in
patients with meningeal cryptococcosis than in those with
extrameningeal infection or controls. Among meningitis
patients, levels of all mediators, except soluble TNF recep-
tor II, were higher in HIV-negative patients than in those
who were HIV-positive [95].
In a phase 2, double-blind, placebo-controlled study of
adjuvant recombinant IFN (rIFN)-c1b in 75 HIV-infected
patients with acute cryptococcal meningitis, 2-week CSF cul-
ture conversion (from positive to negative) occurred in 13%
of placebo recipients vs. 36% of patients receiving 100 lg of
rIFN-c1b three times weekly (p 0.072) and 32% of patients
receiving 200 lg of rIFN-c1b three times weekly (p 0.139).
These results suggest a trend towards more rapid steriliza-
tion of CSF in rIFN-c1b recipients. Combined mycological–
clinical success (negative CSF culture and clinical stability or
improvement at 2 weeks) was observed in 26% of rIFN-c1b
recipients as compared with 8% of controls (p 0.078). Treat-
ment with rIFN-c1b was well tolerated [96].
Ex vivo studies in two patients with severe cryptococcal
meningitis and idiopathic CD4+ lymphopenia revealed
reduced production of IFN-c and TNF-a but not IL-10 in
comparison with healthy controls. In one of these patients
with clinical deterioration despite appropriate antifungal
treatment, adjunctive immunotherapy with rIFN-c was com-
menced (50 lg/m2 three times weekly). Four weeks later,
clinical recovery was almost complete and CSF culture was
negative; because of persistence of low titres of cryptococcal
antigen, mild CSF leukocytosis, and hypoglycorrhachia, how-
ever, treatment with IFN-c was continued for 2 years and
subsequently reduced to 50 lg/m2 once weekly [97].
In a phase 1 dose escalation study, the safety and maxi-
mum tolerated dose of mAb 18B7 were investigated in HIV-
infected patients who had been successfully treated for cryp-
tococcal meningitis. The doses studied ranged from 0.01 to
2 mg/kg of body weight as a single infusion. A modest reduc-
tion in serum cryptococcal antigen titres occurred in the
cohorts receiving doses of 1 and 2 mg/kg; titres tended to
return to baseline measurements by week 12 from the day
of infusion. Doses up to 1 mg/kg were well tolerated [98].
Conclusions
Our knowledge of host defences against cryptococcal infec-
tions has advanced greatly over the past 40 years. Although
the types of immune defect that predispose to progression
from infection to disease have been elucidated, there are still
questions to answer; for example, what are the host factors
leading to development of disease caused by C. gattii in
apparently healthy individuals? The effect of immunomodula-
tory interventions, with mainly cytokines and mAbs, has been
extensively studied in vitro and in vivo. It is now understood
that the outcome of immunotherapy may range from beneﬁ-
cial to deleterious, depending on factors related to the host,
the infecting organism, and the immunomodulatory regimen
employed. The importance of the balance between sufﬁ-
ciently protective Th1 responses and excessive inﬂammation
has also been elucidated. Newer approaches, such as radio-
immunotherapy, provide a promising avenue for therapeutic
alternatives.
Despite this progress, the currently published clinical data
on the adjunctive use of immunotherapy in patients with cryp-
tococcal infections are too limited to lead to ﬁrm recommen-
dations. In the 2010 update of the clinical practice guidelines
for the management of cryptococcal disease by the Infectious
Diseases Society of America, a level B-III recommendation is
made that addition of rIFN-c to the standard antifungal regi-
men can be considered in patients with persistent cryptococ-
cal infection (‘persistent’ being deﬁned as positive CSF
cultures after 4 weeks of antifungal therapy). The recom-
mended regimen is 100 lg/m2 of IFN-c for patients weighing
‡50 kg, and 50 lg/m2 of IFN-c for those weighing <50 kg,
three times weekly for 10 weeks. The usefulness of rIFN-c in
patients with C. gattii infection remains uncertain (C-III) [99].
Patients with cryptococcal disease are likely to be immuno-
compromised, but may well also be in a state of immune
reconstitution. In the latter case, administration of a proin-
ﬂammatory immunomodulator would probably lead to an
excessive inﬂammatory response and a poor outcome;
instead, the use of an anti-inﬂammatory mediator would
probably be beneﬁcial [100]. In this context, the identiﬁca-
tion and validation of surrogate markers characterizing the
patients’ immunological status would help to determine
which patients could beneﬁt from immunotherapy and what
type of immunomodulation should be administered. Such
surrogate markers would probably improve the quality of
relevant clinical studies, eventually leading to valid conclu-
sions and optimal management of cryptococcal disease.
Each of the major immunotherapeutic approaches (passive
immunization, active immunization, and cytokine augmenta-
tion of effector cells) holds promise for advancing the treat-
ment and prevention of cryptococcosis. Among the
promising directions for passive immunotherapy of crypto-
coccosis is the use of targeted radioimmunotherapy [92]. The
fact that radioimmunotherapy was more effective than
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antifungal chemotherapy is particularly promising for the
treatment of refractory disease in profoundly compromised
hosts. From a broader public health perspective, stimulation
of humoral and cellular immune responses following active
vaccination with antigen-loaded glucan particles [101] has the
potential to be widely applied for immunization against C. neo-
formans. With the use of glycoantigens from C. neoformans
[20] that are loaded into glucan particles, dendritic cell, cellu-
lar and humoral immune systems may be activated to provide
protection against cryptococcosis. Given the overwhelming
number of cases and the devastating effect of cryptococcosis
worldwide, a vaccine strategy should clearly play an important
role in reducing the morbidity and mortality resulting from
this infection. Finally, cytokine augmentation remains a prom-
ising modality. Given the encouraging effect of rIFN-c1b in
treatment of acute cryptococcal meningitis in a relatively
small phase 2 study [96], the potential beneﬁts of this strat-
egy warrant further investigation in a larger clinical trial.
Alternatively, consideration of other cytokines, such as IL-18,
an important regulator of innate and acquired immunity, with
demonstrated in vivo effects against experimental cryptococ-
cosis, may also open new clinical options for immunotherapy.
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